Navigation Links
NxStage Reports Record Second Quarter 2011 Financial Results and Raises Revenue Guidance for 2011

LAWRENCE, Mass., Aug. 3, 2011 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today reported record financial results for the second quarter of 2011 ended June 30, 2011, with total revenue well above the top end of its guidance range.


Revenue for the second quarter of 2011 increased to $53.8 million, an increase of 22 percent when compared with revenue of $44.0 million for the second quarter of 2010.  The increase was driven by strong performance across all three markets: Home, Critical Care and In-Center.

The Company grew Home revenue to $27.0 million for the second quarter of 2011, representing an increase of 30 percent when compared with revenue of $20.8 million for the second quarter of 2010. Critical Care revenue grew to $8.6 million for the second quarter of 2011, representing an increase of 29 percent when compared with revenue of $6.7 million for the second quarter of 2010.  Revenue in the In-Center market, from the Company's Medisystems business, increased to $18.2 million for the second quarter of 2011, representing an increase of 10 percent when compared with revenue of $16.5 million for the second quarter of 2010.  

"Building on last quarter's momentum, we delivered strong results across our business and topped expectations," stated Jeffrey H. Burbank, CEO of NxStage Medical, Inc.  "With the first and only truly portable hemodialysis system cleared for home use by the FDA and similar competition still a number of years away, we see significant opportunities for growth, continued innovation and expansion within the Home. Given the strength that we're seeing across all markets and the growth in our opportunity pipeline, we're raising our revenue outlook for 2011 to a range of $210 million to $215 million."

NxStage reported a net loss of $5.6 million, or ($0.10) per share, for the second quarter of 2011 compared with a net loss of $8.3 million, or ($0.17) per share, for the second quarter of 2010.

For the second quarter of 2011, the Company reported Adjusted EBITDA, adjusted for stock-based compensation, deferred revenue recognized, manufacturing transition costs and other non-cash expenses of $1.8 million, compared with an Adjusted EBITDA loss of $0.2 million in the second quarter of 2010.  (See the exhibits for a reconciliation of this non-GAAP measure.)

NxStage announced that it recently concluded its renegotiation of its United States home market agreement with one of its largest customers and signed an amendment to that agreement, extending the term to December 31, 2012, and up to one additional year thereafter.  The amended agreement covers the use of NxStage's products for home hemodialysis.

Separately, NxStage announced that pursuant to its agreement with DaVita, for the period ended June 30, 2011, DaVita achieved System One home patient growth targets that entitled it to become vested in warrants to purchase 250,000 shares of NxStage common stock.  


For the third quarter of 2011, the Company is forecasting revenue to be within a range of $53.5 to $54.5 million.  At this revenue level, the Company would expect a net loss in the range of $5.0 to $6.0 million or ($0.09) to ($0.11) per share, and Adjusted EBITDA in the range of $1.0 to $2.0 million for the third quarter of 2011.  

Supported by its strong performance in the first half of 2011, the Company now anticipates revenue for the 2011 fiscal year to be in a range of $210 to $215 million, compared with its prior guidance for revenues to be in a range of $205 to $213 million.  The Company is maintaining its guidance for a net loss in the range of $19 to $23 million or ($0.36) to ($0.43) per share, and for Adjusted EBITDA to be in the range of $6.0 million to $10.0 million for the 2011 fiscal year.   As a result of the impact of unfavorable foreign exchange and the acceleration of the transition of our blood tubing sets to in-house manufacturing, the Company expects fourth quarter gross margin percentage to be at around the low end of its previously announced guidance of 38 to 42 percent.

This release contains a non-GAAP financial measure.  A reconciliation of the Company's non-GAAP financial measure to its most comparable GAAP financial measure is in the exhibits to this press release.

Conference Call:NxStage will also host a conference call today at 9:00 a.m. Eastern Time to discuss its second quarter financial results. To listen to the conference call, please dial 800.510.9836 (domestic) or 617.614.3670 (international).  The passcode is 68598834.   The call will also be webcast LIVE and can be accessed via the investor relations section of the Company's website at

A replay of the conference call will be available 2 hours after the conclusion of the call through August 10, 2011.  To access the replay dial 888-286-8010 (domestic) or 617-801-6888 (international) and enter passcode 87428332.  An online archive of the conference call can be accessed via the investor relations section of the Company's website at

About NxStageNxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the company's website at

Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to the anticipated demand for the Company's products, anticipated operating results, including revenues, loss, gross margin and Adjusted EBITDA numbers, and other expectations as to future operating results. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements, including market acceptance and demand for NxStage's products, growth in home and/or daily hemodialysis, unanticipated difficulties in achieving operational efficiencies and cost reductions, changes in reimbursement for home and daily hemodialysis, changes in the regulatory environment, changes in the historical purchasing patterns and preferences of our customers, including DaVita Inc., and certain other factors that may affect future operating results and which are detailed in NxStage's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the period ended March 31, 2011.

In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.Contact:Kristen K. Sheppard, Esq.VP, Investor Relationsksheppard@nxstage.comNon-GAAP Financial Measure

The Company discloses a certain non-GAAP financial measure to supplement the Company's consolidated financial statements presented on a GAAP basis. This non-GAAP measure is not in accordance with, or an alternative for, generally accepted accounting principles in the United States and may be different from similar non-GAAP financial measures used by other companies. The non-GAAP financial measure disclosed by the Company is not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP. Management uses Adjusted EBITDA (EBITDA adjusted for stock based-compensation, deferred revenue recognized, manufacturing transition costs and other non-cash expenses) to understand operational cash usage.  The Company believes the non-GAAP financial measure provides useful and supplementary information allowing investors greater transparency to one measure used by management.  The non-GAAP financial measure is meant to supplement, and to be viewed in conjunction with, GAAP financial measures.  The non-GAAP financial measure is reconciled to the most comparable GAAP financial measure below.

NxStage Medical, Inc.Condensed Consolidated Statements of Operations(in thousands, except per share data)(unaudited)Three Months EndedSix Months EndedJune 30,June 30,2011201020112010Revenues

$53,768$44,008$104,332$  84,416Cost of revenues

34,90330,24667,43458,841Gross profit

18,86513,76236,89825,575Operating expenses:Selling and marketing

9,3698,56518,57916,582Research and development


4,4313,6328,5897,043General and administrative

5,4605,64311,04210,581Total operating expenses

22,84921,04245,51640,443Loss from operations

(3,984)(7,280)(8,618)(14,868)Other expense:Interest expense

(1,170)(1,148)(2,327)(2,256)Other (expense) income, net

(170)330(196)213(1,340)(818)(2,523)(2,043)Net loss before income taxes

(5,324)(8,098)(11,141)(16,911)Provision for income taxes

226158419344Net loss

$ (5,550)$ (8,256)$ (11,560)$(17,255)Net loss per share, basic and diluted

$   (0.10)$   (0.17)$
(0.37)Weighted-average shares outstanding, basic and diluted

54,01447,49253,71647,228NxStage Medical, Inc.Condensed Consolidated Balance Sheets(in thousands, except share data)(unaudited)June 30,December 31,20112010ASSETSCurrent assets:Cash and cash equivalents

4,339Accounts receivable, net


39,21334,950Prepaid expenses and other current assets

2,4752,084Total current assets

158,003155,480Property and equipment, net

12,5408,290Field equipment, net

13,03613,660Deferred cost of revenues

40,45840,081Intangible assets, net


42,69842,698Other assets

675473Total assets

286,094LIABILITIES AND STOCKHOLDERS’ EQUITYCurrent liabilities:Accounts payable

$  22,620$
,811Accrued expenses

14,20119,537Current portion of long-term debt

1643Total current liabilities

36,83736,391Deferred revenues

55,99555,366Long-term debt

41,81840,454Other long-term liabilities

5,6391,754Total liabilities

140,289133,965Commitments and contingenciesStockholders’ equity:Undesignated preferred stock: par value $0.001, 5,000,000 shares authorized; no shares issued and outstanding as of June 30, 2011 and December 31, 2010

--Common stock: par value $0.001, 100,000,000 shares authorized; 55,172,136  and 54,043,317 shares issued as of June 30, 2011 and December 31, 2010, respectively

5553Additional paid-in capital

479,186465,642Accumulated deficit

(319,986)(308,426)Accumulated other comprehensive income

39585Treasury stock, at cost: 480,923 and 325,104 shares as of June 30, 2011 and December 31, 2010, respectively

(8,516)(5,225)Total stockholders’ equity

151,134152,129Total liabilities and stockholders’ equity

286,094NxStage Medical, Inc.Cash Flows from Operating Activities(in thousands)(unaudited)Six Months EndedJune 30,20112010Cash flows from operating activities:Net loss

$ (11,560)$ (17,255)Adjustments to reconcile net loss to netcash used in operating activities:Depreciation and amortization

11,45911,077Stock-based compensation


1,7371,128Changes in operating assets and liabilities:Accounts receivable


(13,363)(13,327)Prepaid expenses and other assets

(546)(404)Accounts payable

5,471(399)Accrued expenses and other liabilities

(2,446)3,060Deferred revenues

6298,745Net cash used in operating activities

$   (3,671)$   (1,027)NxStage Medical, Inc.Revenues by Segment(in thousands)Three Months EndedSix Months EndedJune 30,June 30,2011201020112010System One segment  Home

$ 27,013$ 20,815$   53,058$ 39,858  Critical Care

8,5916,65216,02912,711Total System One segment

35,60427,46769,08752,569In-Center segment


$ 53,768$ 44,008$ 104,332$ 84,416NxStage Medical, Inc.Non-GAAP Financial Measures(in millions)(unaudited)Three Months EndedSix Months EndedJune 30,June 30,2011201020112010Net loss

$ (5.6)$ (8.3)$ (11.6)$ (17.3)Less: Depreciation, amortization, interest, and taxes

7.36.514.413.4Less: Adjusting items* EBITDA gain (loss)

$  1.8$ (0.2)$
2.9$   (1.5)* Adjusting items include stock-based compensation, deferred revenue recognized, manufacturing transition costs and other non-cash expensesNxStage Medical, Inc.Non-GAAP Financial Guidance(amounts in millions)Three Months EndedSeptember 30, 2011High

EstimateNet loss

(6.0)Less: Depreciation, amortization, interest, and taxes

6.96.9Less: Adjusting items*

0.10.1Adjusted EBITDA gain

.0* Adjusting items include stock-based compensation, deferred revenue recognized, manufacturing transition costs and other non-cash expenses

SOURCE NxStage Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NxStage® Enters Into New Lease for Corporate Headquarters Within Lawrence, MA
2. NxStage Founder and CEO Jeffrey Burbank Named Ernst & Young Entrepreneur of the Year® 2011 New England Award Winner
3. NxStage Announces Second Quarter 2011 Investor Conference Schedule
4. NxStage® Supports Initiative by Patient Advocacy Groups to Educate Policymakers about the Benefits of Frequent Home Hemodialysis
5. NxStage® Advances Global Growth Strategy with System One™ Regulatory Approval and Distribution Agreement in Australia and New Zealand
6. Chronic Disease Research Group Study Shows Daily Home Hemodialysis Therapy with the NxStage® System One™ is Associated with Lower Risk of Mortality and Higher Survival Estimates Compared to Conventional Thrice-Weekly Dialysis
7. NxStage® Names Michael Miller, Jr. President, International
8. NxStage® to Report First Quarter Fiscal 2011 Financial Results
9. Independent Study Reports 50% Smaller Carbon Footprint With NxStage System One™ vs. Standard In-Center Hemodialysis Machines
10. New NxStage® FREEDOM Data Shows Continued, Marked Benefits for Patients Using the System One™ for Daily Home Hemodialysis Throughout a 12 Month Period
11. In Celebration of the 31st Annual Dialysis Conference, NxStage® Announces Over 5,000 Patients Using the System One™ for Home Hemodialysis
Post Your Comments:
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
(Date:9/19/2017)... Ky. , Sept. 19, 2017   ZirMed Inc ... predictive analytics, today announced that it has been ranked #1 ... Black Book™ Rankings 2017 User Survey. ZirMed was ... solution for large hospitals and medical centers over 200 beds ... Black Book,s healthcare technology user survey history. ...
(Date:9/12/2017)... -- Consumer reviews on the independent review site Consumer Affairs ... for hearing aids, ranking it higher than Miracle Ear ™, ... ... Hearing Aids ... store that provides high performance, state-of-the-art, German-engineered hearing aids directly to ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... agency serving communities in the greater Dallas, Miami, and Raleigh regions, is organizing ... fighting to overcome a rare and deadly chromosome abnormality. , After struggling since ...
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association ... standards of excellence for the field of eating disorders, announces the opening of ... 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. , ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that ... insurance companies have a waiver for care if the client has a cognitive impairment ... family pays for care, is often waived, so the benefits from their insurance start ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
Breaking Medicine News(10 mins):